{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:07:53Z","timestamp":1794582473532,"version":"4.9.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1038\/s41591-020-1086-y","type":"journal-article","created":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T12:07:04Z","timestamp":1602504424000},"page":"1845-1851","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":320,"title":["Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6138-4472","authenticated-orcid":false,"given":"Jianjun","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neema","family":"Navai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9658-2206","authenticated-orcid":false,"given":"Omar","family":"Alhalabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene","family":"Siefker-Radtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1915-4491","authenticated-orcid":false,"given":"Matthew T.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3041-8582","authenticated-orcid":false,"given":"Rebecca Slack","family":"Tidwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surena F.","family":"Matin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Araujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amishi Y.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlos","family":"Msaouel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Corn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John N.","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini S.","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge M.","family":"Blando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5028-3833","authenticated-orcid":false,"given":"Sreyashi","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3899-7868","authenticated-orcid":false,"given":"Yu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc Daniel","family":"Macaluso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5412-9860","authenticated-orcid":false,"given":"Jianhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8663-2671","authenticated-orcid":false,"given":"Andrew","family":"Futreal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Dinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Allison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta","family":"Goswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4658-055X","authenticated-orcid":false,"given":"Padmanee","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,12]]},"reference":[{"key":"1086_CR1","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","volume":"36","author":"A Necchi","year":"2018","unstructured":"Necchi, A. et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study. J. Clin. Oncol. 36, 3353\u20133360 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1086_CR2","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","volume":"25","author":"T Powles","year":"2019","unstructured":"Powles, T. et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat. Med. 25, 1706\u20131714 (2019).","journal-title":"Nat. Med."},{"key":"1086_CR3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.juro.2013.07.061","volume":"191","author":"SH Culp","year":"2014","unstructured":"Culp, S. H. et al. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J. Urol. 191, 40\u201347 (2014).","journal-title":"J. Urol."},{"key":"1086_CR4","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/cncr.27751","volume":"119","author":"AO Siefker-Radtke","year":"2013","unstructured":"Siefker-Radtke, A. O. et al. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. Cancer 119, 540\u2013547 (2013).","journal-title":"Cancer"},{"key":"1086_CR5","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1016\/j.clgc.2016.07.014","volume":"15","author":"M Moschini","year":"2017","unstructured":"Moschini, M. et al. Validation of preoperative risk grouping of the selection of patients most likely to benefit from neoadjuvant chemotherapy before radical cystectomy. Clin. Genitourin. Cancer 15, e267\u2013e273 (2017).","journal-title":"Clin. Genitourin. Cancer"},{"key":"1086_CR6","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1200\/JCO.2013.53.2465","volume":"32","author":"ER Plimack","year":"2014","unstructured":"Plimack, E. R. et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J. Clin. Oncol. 32, 1895\u20131901 (2014).","journal-title":"J. Clin. Oncol."},{"key":"1086_CR7","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","volume":"29","author":"G Griffiths","year":"2011","unstructured":"Griffiths, G., Hall, R., Sylvester, R., Raghavan, D. & Parmar, M. K. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J. Clin. Oncol. 29, 2171\u20132177 (2011).","journal-title":"J. Clin. Oncol."},{"key":"1086_CR8","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.2017.75.0158","volume":"36","author":"G Iyer","year":"2018","unstructured":"Iyer, G. et al. Multicenter prospective phase II trial of neoadjuvant dose-dense gemcitabine plus cisplatin in patients with muscle-invasive bladder cancer. J. Clin. Oncol. 36, 1949\u20131956 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1086_CR9","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","volume":"349","author":"HB Grossman","year":"2003","unstructured":"Grossman, H. B. et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349, 859\u2013866 (2003).","journal-title":"N. Engl. J. Med."},{"key":"1086_CR10","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1002\/cncr.24466","volume":"115","author":"G Sonpavde","year":"2009","unstructured":"Sonpavde, G. et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer 115, 4104\u20134109 (2009).","journal-title":"Cancer"},{"key":"1086_CR11","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.eururo.2011.12.010","volume":"61","author":"R Rosenblatt","year":"2012","unstructured":"Rosenblatt, R. et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur. Urol. 61, 1229\u20131238 (2012).","journal-title":"Eur. Urol."},{"key":"1086_CR12","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","volume":"29","author":"MD Galsky","year":"2011","unstructured":"Galsky, M. D. et al. Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for cisplatin-based chemotherapy. J. Clin. Oncol. 29, 2432\u20132438 (2011).","journal-title":"J. Clin. Oncol."},{"key":"1086_CR13","unstructured":"National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Bladder Cancer, Vol. 2019 (NCCN, 2019)."},{"key":"1086_CR14","doi-asserted-by":"crossref","first-page":"iii40","DOI":"10.1093\/annonc\/mdu223","volume":"25","author":"J Bellmunt","year":"2014","unstructured":"Bellmunt, J. et al. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 25, iii40\u2013iii48 (2014).","journal-title":"Ann. Oncol."},{"key":"1086_CR15","unstructured":"European Association of Urology. European Association of Urology Guidelines (EAU Guidelines Office, 2019)."},{"key":"1086_CR16","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(16)30496-X","volume":"17","author":"P Sharma","year":"2016","unstructured":"Sharma, P. et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1\/2 trial. Lancet Oncol. 17, 1590\u20131598 (2016).","journal-title":"Lancet Oncol."},{"key":"1086_CR17","doi-asserted-by":"crossref","first-page":"e172411","DOI":"10.1001\/jamaoncol.2017.2411","volume":"3","author":"T Powles","year":"2017","unstructured":"Powles, T. et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 open-label study. JAMA Oncol. 3, e172411 (2017).","journal-title":"JAMA Oncol."},{"key":"1086_CR18","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","volume":"391","author":"T Powles","year":"2018","unstructured":"Powles, T. et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 391, 748\u2013757 (2018).","journal-title":"Lancet"},{"key":"1086_CR19","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt, J. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med. 376, 1015\u20131026 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1086_CR20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(17)30900-2","volume":"19","author":"MR Patel","year":"2018","unstructured":"Patel, M. R. et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol. 19, 51\u201364 (2018).","journal-title":"Lancet Oncol."},{"key":"1086_CR21","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","volume":"18","author":"AV Balar","year":"2017","unstructured":"Balar, A. V. et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 18, 1483\u20131492 (2017).","journal-title":"Lancet Oncol."},{"key":"1086_CR22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar, A. V. et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389, 67\u201376 (2017).","journal-title":"Lancet"},{"key":"1086_CR23","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1200\/JCO.2001.19.20.4005","volume":"19","author":"R Millikan","year":"2001","unstructured":"Millikan, R. et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J. Clin. Oncol. 19, 4005\u20134013 (2001).","journal-title":"J. Clin. Oncol."},{"key":"1086_CR24","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122\u2013133 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1086_CR25","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277\u20131290 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1086_CR26","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/annonc\/mdx692","volume":"29","author":"A Bamias","year":"2018","unstructured":"Bamias, A. et al. Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive\/Advanced Cancer of the Urothelium (RISC). Ann. Oncol. 29, 361\u2013369 (2018).","journal-title":"Ann. Oncol."},{"key":"1086_CR27","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.eururo.2019.02.017","volume":"75","author":"J Kim","year":"2019","unstructured":"Kim, J. et al. The cancer genome atlas expression subtypes stratify response to checkpoint inhibition in advanced urothelial cancer and identify a subset of patients with high survival probability. Eur. Urol. 75, 961\u2013964 (2019).","journal-title":"Eur. Urol."},{"key":"1086_CR28","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","volume":"170","author":"SC Wei","year":"2017","unstructured":"Wei, S. C. et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell 170, 1120\u20131133 e1117 (2017).","journal-title":"Cell"},{"key":"1086_CR29","doi-asserted-by":"crossref","first-page":"22699","DOI":"10.1073\/pnas.1821218116","volume":"116","author":"SC Wei","year":"2019","unstructured":"Wei, S. C. et al. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proc. Natl Acad. Sci. USA 116, 22699\u201322709 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1086_CR30","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.immuni.2019.03.004","volume":"50","author":"SC Wei","year":"2019","unstructured":"Wei, S. C. et al. Negative co-stimulation constrains T cell differentiation by imposing boundaries on possible cell states. Immunity 50, 1084\u20131098 (2019).","journal-title":"Immunity"},{"key":"1086_CR31","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/s41588-018-0200-2","volume":"50","author":"D Miao","year":"2018","unstructured":"Miao, D. et al. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat. Genet. 50, 1271\u20131281 (2018).","journal-title":"Nat. Genet."},{"key":"1086_CR32","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1158\/2326-6066.CIR-13-0020","volume":"1","author":"D Ng Tang","year":"2013","unstructured":"Ng Tang, D. et al. Increased frequency of ICOS+CD4+ T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol. Res. 1, 229\u2013234 (2013).","journal-title":"Cancer Immunol. Res."},{"key":"1086_CR33","doi-asserted-by":"crossref","first-page":"14987","DOI":"10.1073\/pnas.0806075105","volume":"105","author":"CI Liakou","year":"2008","unstructured":"Liakou, C. I. et al. CTLA-4 blockade increases IFN-\u03b3-producing CD4++ ICOShihi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc. Natl Acad. Sci. USA 105, 14987\u201314992 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1086_CR34","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1158\/1078-0432.CCR-10-0569","volume":"16","author":"BC Carthon","year":"2010","unstructured":"Carthon, B. C. et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin. Cancer Res. 16, 2861\u20132871 (2010).","journal-title":"Clin. Cancer Res."},{"key":"1086_CR35","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita, R. et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577, 561\u2013565 (2020).","journal-title":"Nature"},{"key":"1086_CR36","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549\u2013555 (2020).","journal-title":"Nature"},{"key":"1086_CR37","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","volume":"577","author":"F Petitprez","year":"2020","unstructured":"Petitprez, F. et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature 577, 556\u2013560 (2020).","journal-title":"Nature"},{"key":"1086_CR38","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","volume":"24","author":"RN Amaria","year":"2018","unstructured":"Amaria, R. N. et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat. Med. 24, 1649\u20131654 (2018).","journal-title":"Nat. Med."},{"key":"1086_CR39","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","volume":"378","author":"PM Forde","year":"2018","unstructured":"Forde, P. M. et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N. Engl. J. Med. 378, 1976\u20131986 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1086_CR40","doi-asserted-by":"crossref","first-page":"v358","DOI":"10.1093\/annonc\/mdz249.003","volume":"30","author":"MS Van der Heijden","year":"2019","unstructured":"Van der Heijden, M. S. et al. Pre-operative ipilimumab and nivolumab in locoregionally advanced, stage III, urothelial cancer (NABUCCO). Ann. Oncol. 30, v358 (2019).","journal-title":"Ann. Oncol."},{"key":"1086_CR41","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/sim.4780140404","volume":"14","author":"PF Thall","year":"1995","unstructured":"Thall, P. F., Simon, R. M. & Estey, E. H. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Stat. Med. 14, 357\u2013379 (1995).","journal-title":"Stat. Med."},{"key":"1086_CR42","doi-asserted-by":"crossref","first-page":"748","DOI":"10.12688\/f1000research.11622.1","volume":"6","author":"M Nowicka","year":"2017","unstructured":"Nowicka, M. et al. CyTOF workflow: differential discovery in high-throughput high-dimensional cytometry datasets. F1000Res 6, 748 (2017).","journal-title":"F1000Res"},{"key":"1086_CR43","doi-asserted-by":"crossref","first-page":"e1000217","DOI":"10.1371\/journal.pcbi.1000217","volume":"4","author":"E Lee","year":"2008","unstructured":"Lee, E., Chuang, H.-Y., Kim, J.-W., Ideker, T. & Lee, D. Inferring pathway activity toward precise disease classification. PLoS Comput. Biol. 4, e1000217 (2008).","journal-title":"PLoS Comput. Biol."},{"key":"1086_CR44","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563 (2014).","journal-title":"Nature"},{"key":"1086_CR45","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows\u2013Wheeler transform. Bioinforma. 25, 1754\u20131760 (2009).","journal-title":"Bioinforma."},{"key":"1086_CR46","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213\u2013219 (2013).","journal-title":"Nat. Biotechnol."},{"key":"1086_CR47","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1093\/bioinformatics\/btp394","volume":"25","author":"K Ye","year":"2009","unstructured":"Ye, K., Schulz, M. H., Long, Q., Apweiler, R. & Ning, Z. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinforma. 25, 2865\u20132871 (2009).","journal-title":"Bioinforma."},{"key":"1086_CR48","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).","journal-title":"Nucleic Acids Res."},{"key":"1086_CR49","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41439-019-0061-y","volume":"6","author":"Y-Y Wang","year":"2019","unstructured":"Wang, Y.-Y. et al. HLA-VBSeq v2: improved HLA calling accuracy with full-length Japanese class-I panel. Hum. Genome Var. 6, 29 (2019).","journal-title":"Hum. Genome Var."},{"key":"1086_CR50","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-016-0264-5","volume":"8","author":"J Hundal","year":"2016","unstructured":"Hundal, J. et al. pVAC-seq: a genome-guided in silico approach to identifying tumor neoantigens. Genome Med. 8, 11 (2016).","journal-title":"Genome Med."},{"key":"1086_CR51","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41588-018-0283-9","volume":"51","author":"J Hundal","year":"2019","unstructured":"Hundal, J. et al. Accounting for proximal variants improves neoantigen prediction. Nat. Genet. 51, 175\u2013179 (2019).","journal-title":"Nat. Genet."},{"key":"1086_CR52","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda, A., Lin, D. C., Assenov, Y., Plass, C. & Koeffler, H. P. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 28, 1747\u20131756 (2018).","journal-title":"Genome Res."},{"key":"1086_CR53","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3390\/cancers11030352","volume":"11","author":"P Nombela","year":"2019","unstructured":"Nombela, P. et al. BRCA2 and other DDR genes in prostate cancer. Cancers 11, 352 (2019).","journal-title":"Cancers"},{"key":"1086_CR54","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ymeth.2014.08.016","volume":"70","author":"EC Stack","year":"2014","unstructured":"Stack, E. C., Wang, C., Roman, K. A. & Hoyt, C. C. Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of tyramide signal amplification, multispectral imaging and multiplex analysis. Methods 70, 46\u201358 (2014).","journal-title":"Methods"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-020-1086-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-020-1086-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-020-1086-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T22:02:25Z","timestamp":1633989745000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-020-1086-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,12]]},"references-count":54,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1086"],"URL":"https:\/\/doi.org\/10.1038\/s41591-020-1086-y","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,12]]},"assertion":[{"value":"13 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.G. served as a consultant on a scientific advisory board for AstraZeneca and received compensation as an advisor. A.M.K. served on a scientific advisory board for AstraZeneca and received compensation as an advisor. A.S.-R. is on a scientific advisory board for AstraZeneca and receives compensation as an advisor. J.B. became an AstraZeneca employee after the work on this manuscript was completed. P.S. and J.P.A. do not have any competing interest with this manuscript. However, they provided a list of all disclosures for transparency. P.S. has ownership in Jounce, BioNTx, Constellation, Oncolytics, BioAtla, Forty-Seven, Apricity, Polaris, Marker Therapeutics, Codiak, ImaginAb, Dragonfly, Lytix, Lava Therapeutics, Infinity Pharma, Adaptive Biotechnologies and Hummingbird. J.P.A. has ownership in Jounce, BioNTx, BioAtla, Forty-Seven, Apricity, Polaris, Marker Therapeutics, Adaptive Biotechnologies and Codiak. P.S. serves as a consultant for Constellation, Jounce, Kite Pharma, Neon, BioAtla, Oncolytics Biotech, Forty-Seven, Polaris, Apricity, Marker Therapeutics, Codiak, ImaginAb, Dragonfly, Lava Therapeutics, Infinity Pharma, Lytix and Hummingbird. J.P.A. serves as a consultant for Jounce, Neon, Forty-Seven, Apricity, Polaris, Marker Therapeutics, Codiak, ImaginAb, Lava Therapeutics, Dragonfly, Lytix and Hummingbird. J.G. serves as a consultant for ARMO Biosciences, CRISPR Therapeutics, Jounce, Nektar, Pfizer, Polaris and Symphogen.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}